Regeneron Pharmaceuticals Inc (REGN)
What changed in recent filings
- Products segment 52% → 38%Sep 30, 2024 → Jun 30, 2026
- Institutions — 4 new · 2 added13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Institutions holding Regeneron Pharmaceuticals Inc
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 2 → 2026 Q2: 6 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Regeneron Pharmaceuticals Inc
Institutions we track that reported holding this stock in their most recent 13F.
- Bridgewater Associates0.13% of portfolio · since 2021 Q2
- Dodge & Cox1.59% of portfolio · since 2021 Q4
- National Pension Service (Korea)0.15% of portfolio · held as of 2026 Q2 or earlier
- Caisse de depot (Quebec)0.22% of portfolio · held as of 2026 Q2 or earlier
- Blackstoneunder 0.01% of portfolio · held as of 2026 Q2 or earlier
- Capital World Investors0.06% of portfolio · held as of 2026 Q2 or earlier
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Company overview
A biotech holding blockbuster antibody drugs such as the macular-degeneration drug Eylea and the atopic-dermatitis drug Dupixent.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Regeneron Pharmaceuticals Inc is classified under the Biotech & Health sector. See peers below.
REGN segment revenue mix trend
Quarterly change in segment revenue share · verified from SEC filings
1 quarter with a different segment breakdown was omitted (filing basis changed).
ETFs holding Regeneron Pharmaceuticals Inc
Per SEC N-PORT · 2026-06-30 · by weight · factual
REGN on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
REGN FAQ
What is Regeneron Pharmaceuticals Inc (REGN)?
A biotech holding blockbuster antibody drugs such as the macular-degeneration drug Eylea and the atopic-dermatitis drug Dupixent.
What sector is Regeneron Pharmaceuticals Inc in?
Regeneron Pharmaceuticals Inc is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
Where can I analyze Regeneron Pharmaceuticals Inc (REGN) stock?
On Stocklore you can see REGN's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.